Immunotherapy Company Announces FDA Acceptance of BLA Resubmission For cSCC Treatment

Checkpoint Therapeutics, Inc. (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for cosibelimab. This investigational anti-PD-L1 antibody is being proposed as a treatment for patients with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or radiation. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of January 3, 2024, to make its decision on the application. $Checkpoint Therapeutics (CKPT.US)$